ClinicalTrials.gg
Not yet recruitingNCT07860567Updated Oct 6, 2026

Clinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match

A Phase 4 interventional study of TECNIS PureSee IOL (Model DEN00V/DET150) and TECNIS PureSee IOL (Model DEN00V/DET150) in Presbyopia Correction, Presbyopia and Dysphotopsia, sponsored by Dr. Daniel H. Chang, MD. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Dr. Daniel H. Chang, MD · Phase 4, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Presbyopia with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Presbyopia · United States.

Planned enrollment
64th of 120
68 · median 75
Started
2026
with 5 others
Phase 4
8 of 131
2 open now
Registered
131st of 131
by date

Among the 131 studies in Presbyopia with a site in United States, this one is the 64th largest by planned enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2026, is one of 8 in phase 4, and was the 131st registered.

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

Browse Presbyopia studies →

Open to participants now

8 of the 131 studies in Presbyopia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Presbyopia studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Presbyopia with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the binocular clinical endpoints of distance, intermediate, and near vision and patient reported outcomes utilizing mini-monovision versus mix-match approaches for the correction of presbyopia with intraocular lenses.

Read the detailed description

Presbyopia, defined as the age-related loss of accommodative amplitude, affects essentially all human beings beyond the age of 45 and impacts the ability of the eye to focus at near distances. Current intraocular lens (IOL) options for cataract patients who desire improved vision across a range of distances include full depth of field (DOFi) IOLs and extended depth of field (EDOF) IOLs. Patients implanted with full depth of field IOLs may sometimes experience dysphotopsias (e.g., glare and halos), particularly at night.

The goal with the correction of presbyopia is to maximize near visual range while minimizing the dysphotopsia profile. Bilateral implantation of extended depth of field lenses with a mini-monovision aim is one way to achieve this goal. EDOF lenses minimize the dysphotopsia profile and a near aim in the non-dominant eye will maximize the near visual range. Another option to achieve this goal is the mix-match approach with EDOF and a DOFi lens. The EDOF IOL minimizes the dysphotopsia profile while DOFi IOL maximizes the near visual range.

The hypothesis is that the mini-monovision and mix-match group will have equivalent uncorrected intermediate visual acuities. The mini-monovision group will have superior visual symptoms and the mix-match group will have superior uncorrected distance and near visual acuity, and spectacle independence.

03

Conditions studied

  • Presbyopia Correction
  • Presbyopia
  • Dysphotopsia
  • Visual Acuity

Keywords

  • Presbyopia
  • Presbyopia Correction
  • Intraocular Lens
  • Cataract
  • Dysphotopsia
  • Spectacle Independence
  • Extended Depth of Focus
  • Depth of Field
  • Range of Vision
  • IOL
  • Halometry
  • TECNIS PureSee IOL
  • TECNIS Odyssey IOL
  • PRVSQ
  • PRSIQ
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum 22 years of age
  • Bilateral cataracts for which posterior chamber IOL implantation has been planned
  • Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with a glare source or 20/40 Snellen or worse without a glare source
  • Potential for postoperative BCDVA of 20/30 Snellen or better
  • Corneal astigmatism:
  • Normal corneal topography
  • Preoperative corneal astigmatism range from 0 D - 2.0 D
  • Expected post-operative astigmatism \< 1.0 D
  • Clear intraocular media other than cataract in each eye
  • Availability, willingness, and sufficient cognitive awareness to comply with examination procedures
  • Signed and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries
  • Ability to understand and respond to a questionnaire in English

Exclusion criteria

Exclusion Criteria:

  • Requiring an intraocular lens power outside the available range of power
  • Any pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils)
  • Irregular corneal astigmatism
  • Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
  • Prior corneal refractive surgery (SMILE, LASIK, LASEK, RK, PRK, etc.) or intraocular surgery. Note: Prophylactic peripheral iridotomies and peripheral laser retinal repairs that, in the opinion of the investigator will not confound study outcomes or increase risk to the subject, are acceptable.
  • Corneal abnormalities such as stromal, epithelial, or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study
  • Inability to achieve keratometric stability for soft contact lens wearers
  • History of PMMA or RGP contact lens wear within the last 5 years
  • Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject
  • Subject with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
  • Use of systemic or ocular medications that may affect vision
  • Prior, current, or anticipated use during the course of the 3 month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
  • Poorly controlled diabetes
  • Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., , connective tissue disease, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable.
  • Known ocular disease or pathology that, in the opinion of the investigator,
  • may affect visual acuity
  • may require surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.)
  • may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
  • Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes
  • Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Mini-Monovision (TECNIS PureSee)

    Participants will receive bilateral TECNIS PureSee IOLs (Model DEN00V/DET150), with the non-dominant eye targeted for a "second minus" near aim to achieve mini-monovision.

    Device: TECNIS PureSee IOL (Model DEN00V/DET150)

  • Experimental
    Mix-Match (TECNIS PureSee + TECNIS Odyssey)

    Participants will receive a TECNIS PureSee IOL (Model DEN00V/DET150) in their dominant eye and a TECNIS Odyssey IOL (Model DRN00V/DRT150) in their non-dominant eye.

    Device: TECNIS PureSee IOL (Model DEN00V/DET150) · Device: TECNIS Odyssey IOL (Model DRN00V/DRT150)

Interventions

  • DeviceTECNIS PureSee IOL (Model DEN00V/DET150)

    Bilateral implantation of the TECNIS PureSee intraocular lens following standard phacoemulsification cataract surgery. The non-dominant eye is intentionally targeted for a "second minus" near focus strategy (mini-monovision).

  • DeviceTECNIS PureSee IOL (Model DEN00V/DET150)

    Implantation of the TECNIS PureSee intraocular lens into the dominant eye following standard phacoemulsification cataract surgery.

  • DeviceTECNIS Odyssey IOL (Model DRN00V/DRT150)

    Implantation of the TECNIS Odyssey intraocular lens into the non-dominant eye following standard phacoemulsification cataract surgery.

06

What researchers measure

Primary outcomes

  1. Binocular UCDVA

    Binocular Uncorrected Distance Visual Acuity

    Time frame: At 3-month postoperative study visit

Secondary outcomes

  1. Binocular UCIVA

    Binocular Uncorrected Intermediate Visual Acuity

    Time frame: At 3-month postoperative study visit

  2. Binocular UCNVA

    Binocular Uncorrected Near Visual Acuity

    Time frame: At 3-month postoperative study visit

  3. Patient Reported Outcomes PRVSQv2

    Patient Reported Outcomes (as recorded by the PRVSQ2 questionnaire). The questionnaire does not generate a scale-based or indexed score. Results are analyzed descriptively, capturing the frequency and distribution of specific visual complaints reported across the study population.

    Time frame: At 3-month postoperative study visit

  4. Patient Reported Outcomes PRSIQv2

    Patient Reported Outcomes (as recorded by the PRSIQ2 questionnaire). The questionnaire does not generate a scale-based or indexed score. Results are analyzed descriptively, capturing the frequency and distribution of specific visual complaints reported across the study population.

    Time frame: At 3-month postoperative study visit.

Other outcomes

  1. Residual Refractive Error

    Residual Refractive Error

    Time frame: At 3-month postoperative study visit

  2. Halometry

    Dysphotopsias Measured by Clinical Halometry

    Time frame: At 3-month postoperative study visit

  3. Spectacle Use

    Patient Reported Spectacle Use

    Time frame: At 3-month postoperative study visit

  4. Other Ocular/Visual Symptoms

    Unsolicited visual or eye-related complaints volunteered by participants rather than specifically probed by the investigator. Serves as a secondary safety or tolerability measure to monitor unexpected sensory side effects. Quantified via non-leading, open-ended questioning during study visits or via non-directed adverse event logging

    Time frame: At 3-month postoperative study visit

  5. Patient Recommendation and Satisfaction

    Patient Recommendation and Satisfaction (as recorded by the PQRS questionnaire). The questionnaire does not generate a scale-based or indexed score. Results are analyzed descriptively, capturing the frequency and distribution of specific visual complaints reported across the study population.

    Time frame: At 3-month postoperative study visit

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 6, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860567
Lead sponsor
Dr. Daniel H. Chang, MD
Responsible party
Dr. Daniel H. Chang, MD (Cataract and Refractive Surgeon and Clinical Research Director, Empire Eye and Laser Center) — Sponsor-investigator
First posted
Oct 6, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Brittany Camirand, BSc, CCRC, COA
Contact
bcamirand@empireeyeandlaser.com
661-325-3937 ext. 203
Isabelle Edgington, COA
Contact
iedgington@empireeyeandlaser.com
661-325-3937 ext. 203
Daniel H Chang, MD
study director · Empire Eye and Laser Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion